We are live on ! Find out more
B

Braidwell Portfolio holdings

AUM $2.7B
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
+3.75%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3B
AUM Growth
-$129M
Cap. Flow
-$282M
Cap. Flow %
-9.39%
Top 10 Hldgs %
30.38%
Holding
102
New
28
Increased
19
Reduced
31
Closed
14

Top Buys

Rank Stock Value
1
IRTC icon
iRhythm Holdings
IRTC
+$56.7M
2
GH icon
Guardant Health
GH
+$50.2M
3
GENB
Generate Biomedicines
GENB
+$43.9M
4
GLUE icon
Monte Rosa Therapeutics
GLUE
+$43.2M
5
ARGX icon
argenx
ARGX
+$42.2M

Top Sells

Rank Stock Value
1
EWTX icon
Edgewise Therapeutics
EWTX
+$82.6M
2
ALGN icon
Align Technology
ALGN
+$59.5M
3
CGON icon
CG Oncology
CGON
+$50.2M
4
RAPT
RAPT Therapeutics
RAPT
+$31.5M
5
LEGN icon
Legend Biotech
LEGN
+$28.2M

Sector Composition

Rank Sector Weight
1 Healthcare 87.27%
2 Miscellaneous 12.42%
3 Financials 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CAI
1
Caris Life Sciences
CAI
$7.24B
$143M 4.78%
8,009,447
+193,305
+2% +$4.23M
NBIX icon
2
Neurocrine Biosciences
NBIX
$15.7B
$85.9M 2.87%
652,121
-99,413
-13% -$13.2M
GKOS icon
3
Glaukos
GKOS
$10.6B
$82.2M 2.74%
763,505
-158,474
-17% -$17.8M
CNTA
4
DELISTED
Centessa Pharmaceuticals
CNTA
$78.9M 2.63%
1,986,768
-201,552
-9% -$5.16M
XENE icon
5
Xenon Pharmaceuticals
XENE
$5.81B
$77.8M 2.6%
1,338,452
-486,624
-27% -$22.4M
DNTH icon
6
Dianthus Therapeutics
DNTH
$5.92B
$75.5M 2.52%
899,364
-374,571
-29% -$21.7M
EWTX icon
7
Edgewise Therapeutics
EWTX
$4.64B
$73.9M 2.47%
2,347,583
-2,863,248
-55% -$82.6M
IRTC icon
8
iRhythm Holdings
IRTC
$3.96B
$72M 2.4%
610,192
+392,847
+181% +$56.7M
NUVL
9
DELISTED
Nuvalent
NUVL
$71.8M 2.39%
700,429
-120,977
-15% -$12.3M
KOD icon
10
Kodiak Sciences
KOD
$2.37B
$69.3M 2.31%
1,818,665
-254,123
-12% -$6.57M
CGON icon
11
CG Oncology
CGON
$6.59B
$66.7M 2.22%
984,783
-885,788
-47% -$50.2M
ARGX icon
12
argenx
ARGX
$64B
$62M 2.07%
84,939
+53,932
+174% +$42.2M
HNGE
13
Hinge Health
HNGE
$7.05B
$56.1M 1.87%
1,455,123
+150,500
+12% +$6.25M
ACAD icon
14
Acadia Pharmaceuticals
ACAD
$5.02B
$55M 1.84%
2,471,199
+439,178
+22% +$10.5M
GLUE icon
15
Monte Rosa Therapeutics
GLUE
$1.14B
$52.7M 1.76%
3,206,574
+2,258,258
+238% +$43.2M
KRYS icon
16
Krystal Biotech
KRYS
$10.4B
$47.1M 1.57%
182,425
-19,676
-10% -$5.24M
SYRE icon
17
Spyre Therapeutics
SYRE
$7.97B
$47.1M 1.57%
932,823
-701,792
-43% -$26.5M
GH icon
18
Guardant Health
GH
$21.7B
$46.2M 1.54%
+499,712
New +$50.2M
TMO icon
19
Thermo Fisher Scientific
TMO
$230B
$45.7M 1.52%
92,915
+12,190
+15% +$6.62M
GENB
20
Generate Biomedicines
GENB
$1.97B
$44.9M 1.5%
+3,592,999
New +$43.9M
MBX
21
MBX Biosciences
MBX
$3.03B
$44.6M 1.49%
1,492,467
+473,867
+47% +$16.1M
BTSG icon
22
BrightSpring Health Services
BTSG
$11.7B
$43.3M 1.44%
1,016,562
-179,224
-15% -$7.22M
CLDX icon
23
Celldex Therapeutics
CLDX
$3.07B
$43M 1.43%
1,356,082
-502,027
-27% -$13.7M
NEO icon
24
NeoGenomics
NEO
$2.32B
$41.7M 1.39%
5,617,402
+984,601
+21% +$10.4M
APGE icon
25
Apogee Therapeutics
APGE
$10.2B
$40.3M 1.34%
478,667
-96,400
-17% -$7M
1
2 3 4

Similar funds

CWM
Connecticut Wealth Management Farmington, Connecticut $2.7B AUM 21.91% 1-Year Est. Return
M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM

Braidwell's Q1 2026 Portfolio in Review

As of Q1 2026, Braidwell held 102 positions worth $3B, down 4.1% from $3.13B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Braidwell withdrew a net $282M in Q1 2026, closing 14 positions and reducing 31 holdings. Its most notable exit was Align Technology, an estimated $59.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Braidwell opened a new position in Guardant Health worth $46.2M.

  • Braidwell's largest Q1 2026 buy was Guardant Health: 499,712 shares worth $46.2M.
  • Braidwell added most to iRhythm Holdings in Q1 2026, an estimated $56.7M increase.
  • Braidwell's biggest Q1 2026 reduction was Edgewise Therapeutics, cutting an estimated $82.6M.
  • Braidwell fully exited Align Technology in Q1 2026, selling an estimated $59.5M.
  • Braidwell's ten largest holdings make up 30% of its $3B portfolio in Q1 2026.
  • Braidwell opened 28 new positions and closed 14 in Q1 2026.
  • Braidwell's portfolio value fell 4.1% quarter-over-quarter to $3B.

Based on Braidwell's 13F filing for Q1 2026, filed 15 May 2026.